CDC42 and neoplasm: Imatinib is a tyrosine kinase (TK) inhibitor that can competitively block the ATP-binding site of the TK receptor, thereby inhibiting a variety of TKs, including PDGFRA and c-Kit, and subsequently suppressing tumor growth and inhibiting signal transduction [57, 58].